Outcome and disease progression in NYHA functional class I and II patients with wild-type transthyretin cardiomyopathy treated with tafamidis

Within 12 months of starting tafamidis, 9% of pa- tients experienced HF hospitalization or death, and up to one-third exhibited markers of disease pro- gression. Baseline NAC/Mondor stage III and a high daily loop diuretic dose were independently associ- ated with adverse outcomes. Using a 12-month landmark analysis, we demonstrated that clinical and biochemical worsening over time was associated with subsequent events. Two progression-based models effectively identified high-risk patients and may help guide treatment decisions in clinical practice as well as serve as potential endpoints for future clinical trials.